Foundry Healthcare RD Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RCUS | ARCUS BIOSCIENCES INC | Healthcare | $3.44B | 5.81% |
2RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 4.87% |
3BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.83B | 4.78% |
4NRIX | NURIX THERAPEUTICS INC | Healthcare | $2.40B | 4.05% |
5AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 3.98% |
6BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 3.92% |
7VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 3.14% |
8SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 3.07% |
9IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 3.00% |
10TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 2.87% |
11VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 2.68% |
12NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 2.68% |
13MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 2.45% |
14NVAX | NOVAVAX INC | Healthcare | $1.35B | 2.28% |
15XNCR | XENCOR INC | Healthcare | $1.30B | 2.19% |
16QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 2.00% |
17TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 1.98% |
18SDGR | SCHRODINGER INC | Healthcare | $1.14B | 1.93% |
19WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 1.89% |
20EYPT | EYEPOINT INC | Healthcare | $1.12B | 1.88% |
21CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 1.84% |
22OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 1.69% |
23VOR | VOR BIOPHARMA INC | Healthcare | $980M | 1.65% |
24KURA | KURA ONCOLOGY INC | Healthcare | $964M | 1.63% |
25ANNX | ANNEXON INC | Healthcare | $950M | 1.60% |
26REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 1.45% |
27SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 1.45% |
28AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 1.22% |
29BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | Healthcare | $686M | 1.16% |
30PHR | PHREESIA INC | Healthcare | $662M | 1.12% |
31NGNE | NEUROGENE INC | Healthcare | $590M | 1.00% |
32MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.99% |
33FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.97% |
34VSTM | VERASTEM INC | Healthcare | $530M | 0.89% |
35ARVN | ARVINAS INC | Healthcare | $517M | 0.87% |
36DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.87% |
37RGNX | REGENXBIO INC | Healthcare | $511M | 0.86% |
38OFIX | ORTHOFIX MEDICAL INC | Healthcare | $468M | 0.79% |
39PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.77% |
40KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.76% |
41VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.75% |
42PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.73% |
43ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.72% |
44CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.69% |
45ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.67% |
46STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.66% |
47UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.64% |
48ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.61% |
49VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.55% |
50LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.52% |
51FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.51% |
52TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.45% |
53RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.41% |
54ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.41% |
55RXST | RXSIGHT INC | Healthcare | $230M | 0.39% |
56SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.38% |
57KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.36% |
58SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.36% |
59KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.36% |
60AGEN | AGENUS INC | Healthcare | $209M | 0.35% |
61IMUX | IMMUNIC INC | Healthcare | $207M | 0.35% |
62DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.34% |
63AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.34% |
64TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.33% |
65KRRO | KORRO BIO INC | Healthcare | $177M | 0.30% |
66ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.29% |
67CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.28% |
68PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.23% |
69VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.22% |
70AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.22% |
71CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.21% |
72SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $120M | 0.20% |
73RLYB | RALLYBIO CORP | Healthcare | $87M | 0.15% |
74ACET | ADICET BIO INC | Healthcare | $76M | 0.13% |
75ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $76M | 0.13% |
76CLNN | CLENE INC | Healthcare | $76M | 0.13% |
77SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.12% |
78LONA | LEONABIO INC | Healthcare | $68M | 0.11% |
79IMA | IMAGENEBIO INC | Healthcare | $61M | 0.10% |
80XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.09% |
81MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.09% |
82TIL | INSTIL BIO INC | Healthcare | $50M | 0.08% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $59.24B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 32% toward Large, 29% toward Growth. +16% unclassified (12 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 82 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 82 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 121.2% | 97.9% |
| 3 yearsp.a. | 21.4% | 11.7% |
| 5 yearsp.a. | 4.8% | 3.4% |
| 10 yearsp.a. | 12.2% | 2.0% |
| Since inceptionp.a. | 17.2% | 10.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 43.8% | 50.8% |
| 2025 | 26.6% | 9.4% |
| 2024 | -5.3% | -16.2% |
| 2023 | 4.7% | -4.1% |
| 2022 | -30.6% | -9.2% |
| 2021 | -1.7% | -18.0% |
| 2020 | 30.7% | 1.5% |
| 2019 | 22.2% | -4.1% |
| 2018 | 0.9% | -4.6% |
| 2017 | 53.0% | 14.5% |
| 2016 | -17.6% | -1.1% |
| 2015 | 23.5% | 21.0% |
| 2014 | 45.0% | 22.0% |
| 2013 | 33.9% | -8.1% |
| 2012 | 38.8% | 19.7% |
| 2011 | 18.8% | 12.5% |
| 2010 | 19.8% | 14.4% |
| 2009 | 109.8% | 87.9% |
| 2008 | -18.9% | 8.1% |
| 2007 | -19.3% | -35.3% |
| 2006 | 11.8% | 14.8% |
| 2005 | 5.8% | -11.3% |
| 2004 | 12.5% | 6.0% |
| 2003 | 71.7% | 31.4% |
| 2002 | -46.8% | -27.3% |
| 2001 | 17.1% | 57.2% |
| 2000 | 144.5% | 153.9% |
| 1999 | 39.9% | 34.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare RD Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a RD signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.